Success Metrics

Clinical Success Rate
88.2%

Based on 15 completed trials

Completion Rate
88%(15/17)
Active Trials
0(0%)
Results Posted
93%(14 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_2
2
11%
Ph phase_3
12
63%
Ph phase_4
2
11%
Ph phase_1
3
16%

Phase Distribution

3

Early Stage

2

Mid Stage

14

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
3(15.8%)
Phase 2Efficacy & side effects
2(10.5%)
Phase 3Large-scale testing
12(63.2%)
Phase 4Post-market surveillance
2(10.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.9%

15 of 19 finished

Non-Completion Rate

21.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(15)
Terminated(4)

Detailed Status

Completed15
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
88.2%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (15.8%)
Phase 22 (10.5%)
Phase 312 (63.2%)
Phase 42 (10.5%)

Trials by Status

terminated211%
withdrawn211%
completed1579%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT02787551Phase 3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Completed
NCT02229227Phase 3

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Completed
NCT02793154Phase 4

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

Terminated
NCT02750930Phase 4

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Terminated
NCT03015519Phase 3

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

Withdrawn
NCT00938158Phase 1

A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

Completed
NCT01077505Phase 1

An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

Completed
NCT01406262Phase 1

Albiglutide Thorough ECG Study in Healthy Volunteers

Completed
NCT01777282Phase 3

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

Completed
NCT01098539Phase 3

A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

Completed
NCT01128894Phase 3

A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

Completed
NCT01098461Phase 2

Dose Ranging Study of Albiglutide in Japanese Subjects

Completed
NCT01475734Phase 2

Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

Completed
NCT00838916Phase 3

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Completed
NCT00839527Phase 3

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

Completed
NCT00849056Phase 3

Safety and Efficacy of Albiglutide in Type 2 Diabetes

Completed
NCT00849017Phase 3

Safety and Efficacy Study of Albiglutide in Type 2 Diabetes

Completed
NCT00838903Phase 3

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Completed
NCT02229240Phase 3

Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus

Withdrawn

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19